TABLE 1.

Comparison of dalbavancin MIC results to those of vancomycin and teicoplanin tested against four gram-positive organism groups^a

Organism	No. of strains tested		Dalbavancin MIC (μg/ml)e	No. (%) of strains for which vancomycin MIC (μg/ml) wasf:			No. (%) of strains for which teicoplanin MIC (μg/ml) was:
	Vancomycin	Teicoplanin		≤1	2	4	≤8	16	≥32
S. aureusb	11,867	11,867	≤0.5	11,472 (96.7)	394 (3.3)	1 (<0.1)	11,865 (>99.9)	2 (<0.1)
					1
Coagulase-negative staphylococcic	3,450	3,450	≤0.5	2,040 (59.1)	1,388 (40.2)	17 (0.5)	3,329 (96.4)	96 (2.8)	20 (0.6)
			1		3 (<0.1)	2 (<0.1)	4 (0.1)		1 (<0.1)
β-Hemolytic streptococcid	1,051	1,050	≤0.5	1,051 (100.0)			1,050 (100.0)
					1
Viridans group streptococcid	381	380	≤0.5	381 (100.0)			380 (100.0)
					1

^aSusceptibility testing was by CLSI methods (4), and a total of 16,749 strains were tested.

^bFor S. aureus, the CLSI susceptibility breakpoint for vancomycin is 2 μg/ml, and that for teicoplanin is ≤8 μg/ml (5).

^cFor coagulase-negative staphylococci, the CLSI susceptibility breakpoint for vancomycin is 4 μg/ml, and that for teicoplanin is ≤8 μg/ml (5).

^dFor β-hemolytic streptococci, the CLSI susceptibility breakpoint for vancomycin is ≤1 μg/ml (5), and intermediate and resistant categories have not been defined. No CLSI interpretive criteria for teicoplanin have been published for streptococcal isolates.

^eTwo possible breakpoints (≤0.5 and ≤1 μg/ml) for dalbavancin were used. Higher concentrations (2 and ≥4 μg/ml) of dalbavancin were also tested, but the MIC of this drug was not higher than 1 μg/ml for any strain.

^fHigher concentrations (8, 16, and ≥32 μg/ml) of vancomycin were also tested, but the MIC of this drug was not higher than 4 μg/ml for any strain.